Amylyx Pharmaceuticals Profit Margin

Amylyx Pharmaceuticals (AMLX) currently reports a profit margin of -Infinity% as of March 2026. That compares with 172.06% in the prior-year period — down Infinity% year over year. That is below the sector sector average of 19.69%. Use the charts on this page to explore Amylyx Pharmaceuticals's profit margin history and peer comparisons.

Amylyx Pharmaceuticals's profit margin decreased from 172.06% to -Infinity% — a Infinity% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Amylyx Pharmaceuticals's profit margin of -Infinity% is lower than the its sector sector average of 19.69%. That is roughly Infinity% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Amylyx Pharmaceuticals's current -Infinity% should be judged against industry norms (sector average: 19.69%) and against AMLX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -Infinity%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 19.69%. From there, open related valuation or income-statement pages for Amylyx Pharmaceuticals, and consider following AMLX for alerts when major investors trade the stock.